OMGAQ (Omega Therapeutics) ROE % Adjusted to Book Value: -59.59% (As of Sep. 2024)


OMGAQ Omega Therapeutics Inc OMGAQ
16 GF Score
Price $0.00
View Full Analysis

What is Omega Therapeutics ROE % Adjusted to Book Value?

Omega Therapeutics OMGAQ +50.00% 16 ROE % Adjusted to Book Value is -59.59% as of Sep. 2024. GuruFocus rates OMGAQ with a GF Score™ of 16/100.

Omega Therapeutics's ROE % for the quarter that ended in Sep. 2024 was -347.98%. Omega Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was 5.84. Omega Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -59.59%.

Omega Therapeutics ROE % Adjusted to Book Value Related Terms

Omega Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Omega Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omega Therapeutics ROE % Adjusted to Book Value Chart

Omega Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
0.00 0.00 -37.19 -25.86 -41.55

Omega Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -66.35 -42.18 -33.28 -44.35 -59.59

OMGAQ vs ENDV, ORGS, PBLA: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Omega Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omega Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omega Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Omega Therapeutics's ROE % Adjusted to Book Value falls into.


OMGAQ
16GF Score
Omega Therapeutics Inc OMGAQ
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Omega Therapeutics ROE % Adjusted to Book Value Calculation

Omega Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-118.82% / 2.86
=-41.55%

Omega Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-347.98% / 5.84
=-59.59%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -59.59% mean?
Omega Therapeutics (OMGAQ) has a ROE % Adjusted to Book Value of -59.59% as of Sep. 2024. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Omega Therapeutics and its competitors.
Is Omega Therapeutics' ROE % Adjusted to Book Value too high?
Omega Therapeutics' current ROE % Adjusted to Book Value is -59.59%. Overall, Omega Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Omega Therapeutics' ROE % Adjusted to Book Value compare to ENDV and ORGS?
Omega Therapeutics' ROE % Adjusted to Book Value of -59.59% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Omega Therapeutics and its competitors. Omega Therapeutics's current ROE % Adjusted to Book Value is -59.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omega Therapeutics stock overvalued right now?
Omega Therapeutics (OMGAQ) has a current ROE % Adjusted to Book Value of -59.59%. The current ROE % Adjusted to Book Value is -59.59%. Omega Therapeutics' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Omega Therapeutics (OMGAQ), the current ROE % Adjusted to Book Value is -59.59% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Omega Therapeutics Business Description

Address 140 First Street, Suite 501, Cambridge, MA, USA, 02141
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
16GF Score

Get the complete analysis for OMGAQ

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price